Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.

Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD, UNITY-1 Study Group.

Open source

DOI: 10.1001/jama.2015.3860
Published: 2015-05-01
Container: JAMA
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jama.2015.3860,
  title = {Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.},
  author = {Poordad F and  Sievert W and  Mollison L and  Bennett M and  Tse E and  Bräu N and  Levin J and  Sepe T and  Lee SS and  Angus P and  Conway B and  Pol S and  Boyer N and  Bronowicki JP and  Jacobson I and  Muir AJ and  Reddy KR and  Tam E and  Ortiz-Lasanta G and  de Lédinghen V and  Sulkowski M and  Boparai N and  McPhee F and  Hughes E and  Swenson ES and  Yin PD and  UNITY-1 Study Group.},
  year = {2015},
  journal = {JAMA},
  doi = {10.1001/jama.2015.3860},
  url = {https://doi.org/10.1001/jama.2015.3860}
}

RIS

TY  - JOUR
TI  - Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
AU  - Poordad F
AU  -  Sievert W
AU  -  Mollison L
AU  -  Bennett M
AU  -  Tse E
AU  -  Bräu N
AU  -  Levin J
AU  -  Sepe T
AU  -  Lee SS
AU  -  Angus P
AU  -  Conway B
AU  -  Pol S
AU  -  Boyer N
AU  -  Bronowicki JP
AU  -  Jacobson I
AU  -  Muir AJ
AU  -  Reddy KR
AU  -  Tam E
AU  -  Ortiz-Lasanta G
AU  -  de Lédinghen V
AU  -  Sulkowski M
AU  -  Boparai N
AU  -  McPhee F
AU  -  Hughes E
AU  -  Swenson ES
AU  -  Yin PD
AU  -  UNITY-1 Study Group.
PY  - 2015
JO  - JAMA
DO  - 10.1001/jama.2015.3860
UR  - https://doi.org/10.1001/jama.2015.3860
ER  -

APA

F, P., W, S., L, M., M, B., E, T., N, B., J, L., T, S., SS, L., P, A., B, C., S, P., N, B., JP, B., I, J., AJ, M., KR, R., E, T., G, O., V, D. L., M, S., N, B., F, M., E, H., ES, S., PD, Y., & Group., U. S. (2015). Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.. JAMA. https://doi.org/10.1001/jama.2015.3860

Source records

europe-pmc · retrieved 2026-09-25T15:07:17.851Z
hal · retrieved 2026-09-25T15:07:17.883Z